Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses

Bibliography

• Rowert-Huber J, Patel MJ, Forschner T, Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007;156(Suppl 3):8-12
   PubMed Web of Science ®Google Scholar
• Goldberg LH, Mamelak AJ. Review ofactinic keratosis. Part I: etiology, epidemiology and clinical presentation. J Drugs Dermatol 2010;9:1125-32
   PubMed Web of Science ®Google Scholar
• Ackerman AB. Solar keratosis is squamous cell carcinoma. Arch Dermatol 2003;139:1216-17
   PubMed Web of Science ®Google Scholar
• Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet 2010;375:673-85
   PubMed Web of Science ®Google Scholar
• Cockerell CJ, Wharton JR. New histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma). J Drugs Dermatol 2005;4:462-7
   PubMedGoogle Scholar
• Yantsos VA, Conrad N, Zabawski E, Cockerell CJ. Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. Semin Cutan Med Surg 1999;18:3-14
   PubMed Web of Science ®Google Scholar
• Gupta AK, Cooper EA, Feldman SR, Fleischer AB Jr. A survey of office visits for actinic keratosis as reported by NAMCS, 1990-1999. National Ambulatory Medical Care Survey. Cutis 2002;70(2 Suppl):8-13
   PubMed Web of Science ®Google Scholar
• Warino L, Tusa M, Camacho F, Frequency and cost of actinic keratosis treatment. Dermatol Surg 2006;32:1045-9
   PubMed Web of Science ®Google Scholar
• Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol 1998;139:1033-9
   PubMed Web of Science ®Google Scholar
• Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000;42(1):4-7
   PubMed Web of Science ®Google Scholar
• Jorizzo JL, Markowitz O, Lebwohl MG, A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol 2010;9:1101-8
   PubMed Web of Science ®Google Scholar
• Ulrich M, Krueger-Corcoran D, Roewert-Huber J, Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses. Dermatology 2010;220:15-24
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Gupta G, Ortonne N, Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment. Exp Dermatol 2010;19:641-7
   PubMed Web of Science ®Google Scholar
• Ulrich M, Maltusch A, Rowert-Huber J, Actinic keratoses: non-invasive diagnosis for field cancerisation. Br J Dermatol 2007;156(Suppl 3):13-17
   PubMedGoogle Scholar
• Spencer JM, Hazan C, Hsiung SH, Robins P. Therapeutic decision making in the therapy of actinic keratoses. J Drugs Dermatol 2005;4:296-301
   PubMedGoogle Scholar
• Kovach BT, Murphy G, Otley CC, Oral retinoids for chemoprevention of skin cancers in organ transplant recipients: results of a survey. Transplant Proc 2006;38:1366-8
   PubMedGoogle Scholar
• Berman B, Amini S, Valins W, Block S. Pharmacotherapy of actinic keratosis. Expert Opin Pharmacother 2009;10:3015-31
   PubMed Web of Science ®Google Scholar
• Micali G, Lacarrubba F, Dinotta F, Treating skin cancer with topical cream. Expert Opin Pharmacother 2010;11:1515-27
   PubMed Web of Science ®Google Scholar
• Jorizzo JL, Carney PS, Ko WT, Fluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: equivalent efficacy with a lower concentration and more convenient dosing schedule. Cutis 2004;74(6 Suppl):18-23
   PubMed Web of Science ®Google Scholar
• Shoimer I, Rosen N, Muhn C. Current management of actinic keratoses. Skin Ther Lett 2010;15:5-7
   PubMedGoogle Scholar
• US FDA safety alerts for human medical products: voltaren gel (diclofenac sodium topical gel) 1% – hepatic effects labeling changes. 9 January 2011. Available from: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm193047.htm
   Google Scholar
• Fecker LF, Stockfleth E, Braun FK, Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP. J Invest Dermatol 2010;130:2098-109
   PubMed Web of Science ®Google Scholar
• Wilson EC. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model. Pharmacoeconomics 2010;28:1055-64
   PubMed Web of Science ®Google Scholar
• Szeimies RM, Matheson RT, Davis SA, Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study. Dermatol Surg 2009;35:586-92
   PubMed Web of Science ®Google Scholar
• Bissonette R, Bergeron A, Liu Y. Large surface photodynamic therapy with aminolevulinic acid: treatment of actinic keratoses and beyond. J Drugs Dermatol 2004;3(1 Suppl):S26-31
   Google Scholar
• Papadavid E, Stratigos AJ, Falagas ME. Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer. Expert Opin Pharmacother 2007;8:1743-55
   PubMed Web of Science ®Google Scholar
• Gaspari AA. Mechanism of action and other potential roles of an immune response modifier. Cutis 2007;79(4 Suppl):36-45
   PubMed Web of Science ®Google Scholar
• Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000;43:S6-11
   PubMed Web of Science ®Google Scholar
• Imiquimod Sigma Aldrich Website Product Number I5159. 9 January 2011. Available from: http://www.sigmaaldrich.com/catalog/ProductDetail
   Google Scholar
• Imbertson LM, Beaurline JM, Couture AM, Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998;110:734-9
   PubMed Web of Science ®Google Scholar
• Schon M, Bong AB, Drewniok C, Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003;95:1138-49
   PubMed Web of Science ®Google Scholar
• Lysa B, Tartler U, Wolf R, Gene expression in actinic keratoses: pharmacological modulation by imiquimod. Br J Dermatol 2004;151:1150-9
   PubMed Web of Science ®Google Scholar
• Torres A, Storey L, Anders M, Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod. Br J Dermatol 2007;157:1132-47
   PubMed Web of Science ®Google Scholar
• Torres A, Storey L, Anders M, Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream. J Transl Med 2007;5:7
   PubMed Web of Science ®Google Scholar
• Edwards L, Ferenczy A, Eron L, Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol 1998;134:25-30
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Dinehart S, Whiting D, Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004;50:714-21
   PubMed Web of Science ®Google Scholar
• Korman N, Moy R, Ling M, Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005;141:467-73
   PubMed Web of Science ®Google Scholar
• Jorizzo J, Dinehart S, Matheson R, Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007;57:265-8
   PubMed Web of Science ®Google Scholar
• Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007;157:133-41
   PubMed Web of Science ®Google Scholar
• Gollnick H, Barona CG, Frank RG, Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol 2008;18:677-82
   PubMed Web of Science ®Google Scholar
• Gollnick H, Barona CG, Frank RG, Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol 2005;15:374-81
   PubMed Web of Science ®Google Scholar
• Gebauer K, Shumack S, Cowen PS. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. Br J Dermatol 2009;161:897-903
   PubMed Web of Science ®Google Scholar
• Ben M'barek L, Mebazaa A, Euvrard S, 5% topical imiquimod tolerance in transplant recipients. Dermatology 2007;215:130-3
   PubMed Web of Science ®Google Scholar
• Haustein UF, Paasch U. Aggressive undifferentiated squamous cell carcinoma in an immunosuppressed patient after kidney transplantation. J Dtsch Dermatol Ges 2005;3:44-6
   PubMedGoogle Scholar
• Piaserico S, Belloni Fortina A, Rigotti P, Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc 2007;39:1847-50
   PubMed Web of Science ®Google Scholar
• Pini AM, Koch S, Scharer L, Eruptive keratoacanthoma following topical imiquimod for in situ squamous cell carcinoma of the skin in a renal transplant recipient. J Am Acad Dermatol 2008;59(5 Suppl):S116-17
   Web of Science ®Google Scholar
• Trakatelli M, Katsanos G, Ulrich C, Efforts to counteract locally the effects of systemic immunosupression: a review on the use of imiquimod, a topical immunostimulator in organ transplant recipients. Int J Immunopathol Pharmacol 2010;23:387-96
   PubMed Web of Science ®Google Scholar
• Ulrich C, Bichel J, Euvrard S, Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007;157(Suppl 2):25-31
   PubMed Web of Science ®Google Scholar
• Ulrich C, Busch JO, Meyer T, Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol 2006;155:451-4
   PubMed Web of Science ®Google Scholar
• Peris K, Micantonio T, Fargnoli MC, Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. J Am Acad Dermatol 2006;55:324-7
   PubMed Web of Science ®Google Scholar
• Patel GK, Goodwin R, Chawla M, Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006;54:1025-32
   PubMed Web of Science ®Google Scholar
• van Egmond S, Hoedemaker C, Sinclair R. Successful treatment of perianal Bowen's disease with imiquimod. Int J Dermatol 2007;46:318-19
   PubMed Web of Science ®Google Scholar
• Rosen T, Harting M, Gibson M. Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study. Dermatol Surg 2007;33(4):427-32
   PubMed Web of Science ®Google Scholar
• Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 2005;141:510-14
   PubMedGoogle Scholar
• Spenny ML, Walford J, Werchniak AE, Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis 2007;79:149-52
   PubMed Web of Science ®Google Scholar
• Ray CM, Kluk M, Grin CM, Grant-Kels JM. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int J Dermatol 2005;44:428-34
   PubMedGoogle Scholar
• Lonsdale-Eccles AA, Morgan JM, Nagarajan S, Cruickshank DJ. Successful treatment of vulval melanoma in situ with topical 5% imiquimod cream. Br J Dermatol 2006;155:215-17
   PubMed Web of Science ®Google Scholar
• Nagore E, Botella-Estrada R, Sanmartin O, Guillen C. Imiquimod for the treatment of skin metastases of melanoma. Actas Dermosifiliogr 2005;96:549-50
   PubMedGoogle Scholar
• Turza K, Dengel LT, Harris RC, Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol 2010;37(1):94-8
   Google Scholar
• Heber G, Helbig D, Ponitzsch I, Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy. J Dtsch Dermatol Ges 2009;7:534-6
   PubMed Web of Science ®Google Scholar
• O'Mahony C. Difficult wart cases – use of imiquimod cream 5%. Int J STD AIDS 2001;12:400-3
   PubMed Web of Science ®Google Scholar
• Leong CM, Tarbotton J, Hibma M. Self-applied treatment of persistent plantar wart with 5% imiquimod cream. NZ Med J 2007;120:U2668
   Google Scholar
• Iavazzo C, Pitsouni E, Athanasiou S, Falagas ME. Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. Int J Gynaecol Obstet 2008;101:3-10
   PubMed Web of Science ®Google Scholar
• Kulp J, Levy S, Fein MC, Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp. Arch Dermatol Res 2010;302:539-44
   PubMed Web of Science ®Google Scholar
• Harrison LI, Skinner SL, Marbury TC, Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res 2004;296:6-11
   PubMed Web of Science ®Google Scholar
• Callen JP, Bickers DR, Moy RL. Actinic keratoses. J Am Acad Dermatol 1997;36:650-3
   PubMed Web of Science ®Google Scholar
• Swanson N, Abramovits W, Berman B, Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010;62:582-90
   PubMed Web of Science ®Google Scholar
• Hanke CW, Beer KR, Stockfleth E, Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol 2010;62:573-81
   PubMed Web of Science ®Google Scholar
• Szeimies RM, Gerritsen MJ, Gupta G, Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004;51:547-55
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Sterry W, Carey-Yard M, Bichel J. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol 2007;157(Suppl 2):41-6
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Ulrich C, Lange-Asschenfeldt B, Treatment of multiple, multiform actinic keratoses on the head with imiquimod 5% cream. Eur J Dermatol 2009;19:355-9
   PubMed Web of Science ®Google Scholar
• Gupta AK, Davey V, McPhail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg 2005;9:209-14
   PubMed Web of Science ®Google Scholar
• Krawtchenko N, Roewert-Huber J, Ulrich M, A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007;157(Suppl 2):34-40
   PubMed Web of Science ®Google Scholar
• Sotiriou E, Apalla Z, Maliamani F, Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. J Eur Acad Dermatol Venereol 2009;23:1061-5
   PubMed Web of Science ®Google Scholar
• Kose O, Koc E, Erbil AH, Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. J Dermatolog Treat 2008;19:159-63
   PubMed Web of Science ®Google Scholar
• Van der Geer S, Krekels GA. Treatment of actinic keratoses on the dorsum of the hands: ALA-PDT versus diclofenac 3% gel followed by ALA-PDT. A placebo-controlled, double-blind, pilot study. J Dermatolog Treat 2009;20:259-65
   PubMed Web of Science ®Google Scholar
• Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol 2008;7:669-73
   PubMed Web of Science ®Google Scholar
• Shaffelburg M. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream. J Drugs Dermatol 2009;8:35-9
   PubMed Web of Science ®Google Scholar
• Lee PK, Harwell WB, Loven KH, Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. Dermatol Surg 2005;31:659-64
   PubMed Web of Science ®Google Scholar
• Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol Surg 2000;26:728-32
   PubMed Web of Science ®Google Scholar
• Nelson C, Rigel D. Long-term follow-up of diclofenac sodium 3% in 2.5% hyaluronic acid gel for actinic keratosis: one-year evaluation. J Clin Aesthet Dermatol 2009;2:20-5
   PubMedGoogle Scholar
• Serra-Guillen C, Nagore E, Hueso L, A randomised comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolevulinate. Br J Dermatol 2010. Doi: 10.1111/j.1365-2133.2010.10098.x
   Google Scholar